66 results on '"Christian Haass"'
Search Results
2. Soluble TREM2 drives earliest amyloid‐related p‐tau increase in Alzheimer’s disease but attenuates neurodegeneration in advanced disease
3. Longitudinal increase of sTREM2 in CSF and its relationship with other biomarkers and cognition along the evolution of autosomal dominant Alzheimer’s disease
4. Tau spreads across connected brain regions in progressive supranuclear palsy and corticobasal syndrome
5. Glitter in the darkness? Non‐fibrillar β‐amyloid plaque components significantly impact the β‐amyloid PET signal
6. Associations between sex, body mass index, and the individual microglial response in Alzheimer’s disease
7. Higher TREM2 levels and microglia activation associated with slower rates of amyloid PET increase in humans and a transgenic mouse model of beta‐amyloid
8. Microglial activation and brain networks in Alzheimer’s disease: The ActiGliA cohort study
9. 18 F‐PI‐2620 tau‐PET in corticobasal syndrome (ActiGliA cohort)
10. Higher CSF STREM2/P‐tau ratio levels attenuate effects of polygenic Alzheimer’s disease risk on cognitive decline and neurodegeneration
11. Asymmetry of plaque burden in amyloid mouse models
12. Neuropathological characteristics associated with a recently identified rare PSEN1 deletion mutation (F175del)
13. Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease
14. P4-544: DEEP PROTEOME ANALYSIS IN CEREBROSPINAL FLUID OF MOUSE MODELS FOR NEURODEGENERATIVE DISEASES SUGGESTS A PANEL OF NOVEL BIOMARKERS RELATED TO MICROGLIA ACTIVATION
15. [F5–03–01]: BIOLOGICAL ACTIONS OF TREM2 IN ALZHEIMER'S DISEASE
16. [O1–02–06]: ELEVATED CSF STREM2 IN AUTOSOMAL DOMINANTLY INHERITED ALZHEIMER's DISEASE ASSOCIATED WITH REGIONAL FIBER TRACT INJURY: RESULTS FROM THE DIAN STUDY
17. O3-12-05: INCREASED CSF SOLUBLE TREM2 IS ASSOCIATED WITH AMELIORATED LONGITUDINAL COGNITIVE AND CLINICAL DECLINE IN ALZHEIMER'S DISEASE
18. F5‐02‐04: CSF STREM2 Levels Increase in Early Stages of Autosomal Dominant Alzheimer’s Disease (ADAD) and are Associated with Markers of Neuronal Injury
19. IC‐P‐115: CSF Levels of Strem2 are Associated With Greater Frontal Cortical Thickness During Advanced Disease Stages in Autosomal Dominant Alzheimer Disease
20. IC‐02‐05: Cerebrospinal Fluid Strem2 Levels are Associated with Gray Matter Volume Increases and Reduced Diffusivity in Early Alzheimer’s Disease
21. O1‐10‐04: MONITORING OF LONG‐TERM GAMMA SECRETASE MODULATION TREATMENT IN APP‐SWE MICE BY MEANS OF [18F]‐FLORBETABEN PET
22. IC‐P‐040: PET imaging using [18F]florbetaben in Alzheimer's disease mouse models
23. O1–08–05: Distinct functions of BACE1 and BACE2 in neuregulin processing and melanocyte migration
24. P1–081: Identification of an alternative APP processing pathway
25. P4–010: Cross‐inhibition of beta‐amyloid plaque formation by alpha‐synuclein
26. IC‐P‐001: Longitudinal imaging of cerebral Aβ in APP‐Swe mice using [18F]florbetaben PET
27. O1‐06‐04: Therapeutic potential of BACE1/beta‐secretase: Proteome‐wide identification of physiological BACE1 substrates in primary neurons and mouse brain
28. P1‐134: Longitudinal imaging of cerebral beta‐amyloid in APP‐swe mice using [18F]florbetaben PET
29. P2‐318: Biological consequences of BACE1‐dependent processing of neuregulin
30. P3‐165: Elevated levels of soluble, high molecular weight SDS‐denaturable Aβ‐aggregates are associated with dendritic degeneration in APP‐transgenic mouse models
31. S1‐02‐04: Tauopathy in zebrafish using life imaging transgenic zebrafish
32. O4‐03‐08: TDP‐43 and FUS have different requirements for stress granule localization
33. O1‐05‐07: Gamma‐secretase modulator resistance can be overcome for many pathogenic presenilin mutants by second‐generation compounds
34. P2‐307: A stable G‐quadruplex within the ADAM10 5'‐UTR is involved in translational repression of ADAM10
35. O2‐03‐02: Stepwise autoproteolysis of presenilin 1 is affected by familial Alzheimer's disease mutations
36. O4‐03‐06: Familial Als‐associated Fused in Sarcoma (fus) Mutations Disrupt Transportin‐mediated Nuclear Import
37. P4‐296: Novel APLP1 Peptide In CSF Is Useful For Diagnosis Of Sporadic Alzheimer's Disease
38. P1‐168: Substrate requirements and mechanisms of intramembrane proteolysis by gamma‐secretase and related proteases
39. O1‐03‐02: In vivo analysis of methylene blue and kinase inhibitors in a Tau transgenic zebrafish model
40. P4‐147: Systematic identification of proteases with alpha‐secretase activity
41. O1‐05‐02: Structural and functional analysis of γ ‐secretase and its protease active site domain
42. P3‐335: Upstream of N‐ras (UNR) is involved in translational control of ADAM10 protein expression
43. O1‐04–01: Novel drugs simultaneously modulate both beta‐ and gamma‐secretase cleavage of the amyloid precursor protein
44. P4‐188: Intramembrane cleavage of TNFalpha by SPPL2b carrying a familial Alzheimer's disease‐like mutation
45. O4‐03–04: Mutational analysis of the GxGD‐protease active‐site domain of presenilin 1 reveals structural requirements for γ‐secretase substrate binding and cleavage
46. P1‐032: BACE1 dependent proteolysis of neuregulin in vitro and in vivo
47. S4‐01–06: Mechanisms of intramembrane proteolysis by gamma‐secretase and related proteases
48. P2‐371: Characterization of cell‐permeable BACE‐1 inhibitors in primary neurons and mice
49. P3–391: APH–1 variants differentially contribute to γ–secretase complex assembly and enzymatic activity
50. P3–397: Functional analysis of the protease active site domain of presenilin: Implications for γ–secretase substrate identification
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.